Hillhouse Capital Advisors
Multi-Strategy- Manager
- Hillhouse Capital Advisors
- Quarter
- Q2 2026
- Filed
- 2026-08-14
- 13F value
- $832.1M
- Positions
- 35
- CIK
- 0001762304
Weights are % of 13F book — no reported capital figure for this filer.i
| # | # Shares | Source | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | Legend Biotech CorpLEGNHISTORY | 20.77% | — | $172.8M | 5,984,550 | — | 1.62% | 13F |
| 2 | Futu Hldgs LTDFUTUHISTORY | 19.92% | +24.6% | $165.8M | 1,768,283 | +348,800 | 0.16% | 13F |
| 3 | Arrivent Biopharma IncAVBPHISTORY | 16.40% | — | $136.5M | 3,929,117 | — | 7.97% | 13F |
| 4 | Marvell Technology IncMRVLHISTORY | 5.83% | (4.7%) | $48.5M | 162,933 | (8,100) | 0.02% | 13F |
| 5 | Vipshop Hldgs LTDVIPSHISTORY | 5.53% | +2,683.0% | $46.0M | 3,470,400 | +3,345,700 | 3.43% | 13F |
| 6 | PDD Holdings IncPDDHISTORY | 4.58% | (88.0%) | $38.1M | 500,000 | (3,665,029) | 0.01% | 13F |
| 7 | Ke Hldgs IncBEKEHISTORY | 3.87% | (47.6%) | $32.2M | 2,218,377 | (2,017,901) | — | 13F |
| 8 | Cytek Biosciences IncCTKBHISTORY | 3.54% | — | $29.5M | 6,657,030 | — | 5.12% | 13F |
| 9 | Alamar Biosciences IncALMRHISTORY | 3.11% | NEW | $25.9M | 956,462 | +956,462 | 1.38% | 13F |
| 10 | Alibaba Group Hldg LTDBABAHISTORY | 2.12% | (92.5%) | $17.7M | 183,934 | (2,269,723) | 0.01% | 13F |
| 11 | Odyssey Therapeutics IncODTXHISTORY | 1.87% | NEW | $15.6M | 831,656 | +831,656 | 1.73% | 13F |
| 12 | Yatsen Hldg LTDYSGHISTORY | 1.86% | — | $15.5M | 4,885,873 | — | 0.26% | 13F |
| 13 | Novabridge BiosciencesNBPHISTORY | 1.40% | — | $11.7M | 5,980,568 | — | 2.25% | 13F |
| 14 | Contineum Therapeutics IncCTNMHISTORY | 1.32% | — | $11.0M | 669,337 | — | 2.90% | 13F |
| 15 | Maze Therapeutics IncMAZEHISTORY | 1.31% | — | $10.9M | 366,028 | — | 0.66% | 13F |
| 16 | Agora IncAPIHISTORY | 1.01% | — | $8.4M | 2,098,553 | — | 0.57% | 13F |
| 17 | Taiwan Semiconductor ManufacTSMHISTORY | 0.89% | (0.1%) | $7.4M | 15,510 | (10) | 0.00% | 13F |
| 18 | Sagimet Biosciences IncSGMTHISTORY | 0.67% | — | $5.6M | 724,800 | — | 2.36% | 13F |
| 19 | Netease Com IncNTESHISTORY | 0.54% | NEW | $4.5M | 34,999 | +34,999 | 0.00% | 13F |
| 20 | GE AerospaceGEHISTORY | 0.45% | — | $3.8M | 10,043 | — | 0.00% | 13F |
| 21 | Lumentum Hldgs IncLITEHISTORY | 0.34% | +120.0% | $2.8M | 3,300 | +1,800 | 0.00% | 13F |
| 22 | Nvidia CorporationNVDAHISTORY | 0.34% | +112.6% | $2.8M | 14,054 | +7,444 | 0.00% | 13F |
| 23 | Tuya IncTUYAHISTORY | 0.33% | — | $2.8M | 1,564,400 | — | 0.26% | 13F |
| 24 | Corning IncGLWHISTORY | 0.32% | +33.3% | $2.6M | 10,266 | +2,566 | 0.00% | 13F |
| 25 | Coherent CorpCOHRHISTORY | 0.30% | +50.1% | $2.5M | 6,417 | +2,142 | 0.00% | 13F |
| 26 | Webull CorpBULLHISTORY | 0.24% | (79.3%) | $2.0M | 309,857 | (1,190,143) | 0.08% | 13F |
| 27 | Intel CorpINTCHISTORY | 0.24% | (50.6%) | $2.0M | 14,300 | (14,670) | 0.00% | 13F |
| 28 | Pacific Biosciences Calif InPACBHISTORY | 0.19% | — | $1.5M | 918,892 | — | 0.30% | 13F |
| 29 | Texas Instrs IncTXNHISTORY | 0.17% | NEW | $1.4M | 4,800 | +4,800 | 0.00% | 13F |
| 30 | Mogu IncMOGUHISTORY | 0.17% | — | $1.4M | 847,510 | — | 0.03% | 13F |
| 31 | Gossamer Bio IncGOSSHISTORY | 0.10% | — | $0.8M | 4,974,041 | — | 1.02% | 13F |
| 32 | Equinox Gold CorpEQXHISTORY | 0.09% | — | $0.8M | 80,500 | — | 0.01% | 13F |
| 33 | Zoom Communications IncZMHISTORY | 0.09% | NEW | $0.8M | 9,010 | +9,010 | 0.00% | 13F |
| 34 | Aligos Therapeutics IncALGSHISTORY | 0.05% | — | $0.4M | 76,247 | — | 0.18% | 13F |
| 35 | Ridgetech IncRDGTHISTORY | <0.01% | NEW | $<0.1M | 136 | +136 | 0.00% | 13F |
Positions are from the latest 13F-HR (period end 2026-06-30). Weights are calculated: position value ÷ the 13F book. Schedule 13D/13G stakes are merged in when present (shares and percent of class, no dollar value). Chg Shares and % Chg compare with the adjacent prior quarter's 13F only. % Out is either calculated (position shares ÷ issuer shares outstanding from the issuer's XBRL cover page; weighted-average basic shares as a fallback) or reported (percent of class on a Schedule 13D/13G newer than the 13F period) — hover a value for its source and date. Unavailable figures show “—”, never an estimate. Methodology